Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

  • Johnson, Sterling C.
  • Suárez-Calvet, Marc
  • Suridjan, Ivonne
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Jonaitis, Erin
  • Michna, Agatha
  • Carboni, Margherita
  • Bittner, Tobias
  • Rabe, Christina
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
Background: Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum. Methods: Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β1-42, amyloid-β1-40, and alpha-synuclein), and results between cohorts for each disease stage were compared. The relationship between CSF biomarker concentration and cognitive scores was evaluated. Results: Biomarker distributions were comparable across cohorts following correction. Correlations of biomarker values were consistent across cohorts, regardless of disease stage. Disease stage differentiation was highest for neurofilament light (NfL), phosphorylated tau, and total tau, regardless of the cohort. Correlation between biomarker concentration and cognitive scores was comparable across cohorts, and strongest for NfL, chitinase-3-like protein-1 (YKL40), and glial fibrillary acidic protein. Discussion: The precision of the NTK enables merging of biomarker datasets, after correction for preanalytical confounders. Assessment of multiple cohorts is crucial to increase power in future studies into AD pathogenesis., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). For the Wisconsin studies, CSF assay kits were provided by Roche Diagnostics GmbH. Data were collected under the following grants from the NIH National Institute of Aging: R01 AG027161, R01 AG037639, R01AG054059 UF1AG051216, P50 AG033514, and P30 AG062715. Support was also provided by the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 (Clinical and Translational Sciences). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie (grant agreement No. 847648; LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institute of Health (NIH), USA (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression

  • Pelkmans, Wiesje
  • Gispert, Juan Domingo
This scientific commentary refers to 'Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline' by Peretti et al. (https://doi.org/10.1093/brain/awae211)., J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: data from the European Prevention of Alzheimer's Disease (EPAD) cohort

  • Brugulat Serrat, Anna, 1986-
  • Tsoy, Elena
  • Sánchez Benavides, Gonzalo
  • Milà Alomà, Marta
  • Gaynor, Leslie S.
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Kramer, Joel H.
  • Possin, Katherine L.
  • European Prevention of Alzheimer's Disease (EPAD) Consortium
INTRODUCTION: Sensitive memory paradigms may allow the detection of subtle memory changes associated with early Alzheimer's pathology in individuals without established clinical symptomatology. METHODS: We explored the cross-sectional association between performance on Tablet-based Cognitive Assessment Tool (TabCAT) Favorites, a brief computerized memory test, with cerebrospinal fluid AT status (A for amyloid-ß and T for phosphorylated tau) and its discriminative validity in 727 clinically asymptomatic participants from the European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study. Episodic memory was also evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-MI). RESULTS: Compared to A-T- individuals, poorer TabCAT Favorites Total Correct (Favorites-TC) cross-sectional performance was associated with an increased likelihood of A+T+ status, but not A+T- status. There were no significant associations between AT status and RBANS-MI. Among individuals with low Favorites-TC performance, AT status predicted progression on the Clinical Dementia Rating > 0. DISCUSSION: Favorites-TC is a sensitive measure for the early detection of cognitive changes in the early stages of the AD continuum. Highlights: We explored Tablet-based Cognitive Assessment Tool (TabCAT) Favorites scores and cerebrospinal fluid (CSF) AT status (A for amyloid-ß and T for phosphorylated tau) in asymptomatic individuals. Poorer Favorites performance linked to higher A+T+ likelihood. TabCAT Favorites is a sensitive tool for detecting early cognitive changes in Alzheimer's disease (AD)., The authors express their most sincere gratitude to the EPAD LCS participants. This work used data and/or samples from the EPAD project, which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer's Association Grant [SG-21-818099-EPAD]. AB-S receives funding from Alzheimer's Association Clinician Scientist Fellowship Program (AACSF-23-1145154). ET received funding from the NIH (R21AG080410, R35AG072362, U01NS128913, P30AG062422, R01AG059183, and UG3AG090679) and Global Brain Health Institute. GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. MM-A receives funding from Alzheimer's Association Research Fellowship Program (AARF-23-1141384). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). JDG DG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). KP receives funding from the NIH (U01NS128913, UH3NS105557, and R35AG072362), Quest Diagnostics, the Global Brain Health Institute, the Merck Foundation, and the Rainwater Charitable Foundation.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Spatial-temporal patterns of β-amyloid accumulation: a subtype and stage inference model analysis

  • Collij, Lyduine E.
  • Salvadó, Gemma
  • Wottschel, Viktor
  • Mastenbroek, Sophie E.
  • Schoenmakers, Pierre
  • Heeman, Fiona
  • Aksman, Leon
  • Wink, Alle Meije
  • Berckel, Bart N.M.
  • van de Flier, Wiesje M.
  • Scheltens, Philip
  • Visser, Pieter Jelle
  • Barkhof, Frederik
  • Haller, Sven
  • Gispert, Juan Domingo
  • Lopes Alves, Isadora
  • Alzheimer’s Disease Neuroimaging Initiative
  • ALFA Study
Background and objectives: β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data. Methods: amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression. Results: participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were APOE ε4 carriers, and 51.8% were female. A 1-subtype model recovered the traditional amyloid accumulation trajectory, but SuStaIn identified 3 optimal subtypes, referred to as frontal, parietal, and occipital based on the first regions to show abnormality. Of the 788 (26.2%) with strong subtype assignment (>50% probability), the majority was assigned to frontal (n = 415 [52.5%]), followed by parietal (n = 199 [25.3%]) and occipital subtypes (n = 175 [22.2%]). Significant differences across subtypes included distinct proportions of APOE ε4 carriers (frontal 61.8%, parietal 57.1%, occipital 49.4%), participants with dementia (frontal 19.7%, parietal 19.1%, occipital 31.0%), and lower age for the parietal subtype (frontal/occipital 72.1 years, parietal 69.3 years). Higher amyloid (Centiloid) and CSF p-tau burden was observed for the frontal subtype; parietal and occipital subtypes did not differ. At follow-up, most participants (81.1%) maintained baseline subtype assignment and 25.6% progressed to a later stage. Discussion: whereas a 1-trajectory model recovers the established pattern of amyloid accumulation, SuStaIn determined that 3 subtypes were optimal, showing distinct associations with Alzheimer disease risk factors. Further analyses to determine clinical utility are warranted., The project leading to this article has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither the Innovative Medicines Initiative nor the European Union or EFPIA are liable for any use of the information contained herein. The ALFA study received funding from “la Caixa” Foundation (ID 100010434) under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and the Agencia Estatal de Investigación Proyectos de I+D+i Retos Investigación (RTI2018-102261-B-I00).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression

  • Pelkmans, Wiesje
  • Gispert López, Juan Domingo
This scientific commentary refers to 'Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline' by Peretti et al. (https://doi.org/10.1093/brain/awae211)., J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: data from the European Prevention of Alzheimer's Disease (EPAD) cohort

  • Brugulat Serrat, Anna, 1986-
  • Tsoy, Elena
  • Sánchez Benavides, Gonzalo
  • Milà Alomà, Marta
  • Gaynor, Leslie S.
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Kramer, Joel H.
  • Possin, Katherine L.
  • European Prevention of Alzheimer's Disease (EPAD) Consortium
INTRODUCTION: Sensitive memory paradigms may allow the detection of subtle memory changes associated with early Alzheimer's pathology in individuals without established clinical symptomatology. METHODS: We explored the cross-sectional association between performance on Tablet-based Cognitive Assessment Tool (TabCAT) Favorites, a brief computerized memory test, with cerebrospinal fluid AT status (A for amyloid-ß and T for phosphorylated tau) and its discriminative validity in 727 clinically asymptomatic participants from the European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study. Episodic memory was also evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-MI). RESULTS: Compared to A-T- individuals, poorer TabCAT Favorites Total Correct (Favorites-TC) cross-sectional performance was associated with an increased likelihood of A+T+ status, but not A+T- status. There were no significant associations between AT status and RBANS-MI. Among individuals with low Favorites-TC performance, AT status predicted progression on the Clinical Dementia Rating > 0. DISCUSSION: Favorites-TC is a sensitive measure for the early detection of cognitive changes in the early stages of the AD continuum. Highlights: We explored Tablet-based Cognitive Assessment Tool (TabCAT) Favorites scores and cerebrospinal fluid (CSF) AT status (A for amyloid-ß and T for phosphorylated tau) in asymptomatic individuals. Poorer Favorites performance linked to higher A+T+ likelihood. TabCAT Favorites is a sensitive tool for detecting early cognitive changes in Alzheimer's disease (AD)., The authors express their most sincere gratitude to the EPAD LCS participants. This work used data and/or samples from the EPAD project, which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer's Association Grant [SG-21-818099-EPAD]. AB-S receives funding from Alzheimer's Association Clinician Scientist Fellowship Program (AACSF-23-1145154). ET received funding from the NIH (R21AG080410, R35AG072362, U01NS128913, P30AG062422, R01AG059183, and UG3AG090679) and Global Brain Health Institute. GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. MM-A receives funding from Alzheimer's Association Research Fellowship Program (AARF-23-1141384). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). JDG DG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). KP receives funding from the NIH (U01NS128913, UH3NS105557, and R35AG072362), Quest Diagnostics, the Global Brain Health Institute, the Merck Foundation, and the Rainwater Charitable Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

  • Johnson, Sterling C.
  • Suárez-Calvet, Marc
  • Suridjan, Ivonne
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Jonaitis, Erin
  • Michna, Agatha
  • Carboni, Margherita
  • Bittner, Tobias
  • Rabe, Christina
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
Background: Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum. Methods: Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β1-42, amyloid-β1-40, and alpha-synuclein), and results between cohorts for each disease stage were compared. The relationship between CSF biomarker concentration and cognitive scores was evaluated. Results: Biomarker distributions were comparable across cohorts following correction. Correlations of biomarker values were consistent across cohorts, regardless of disease stage. Disease stage differentiation was highest for neurofilament light (NfL), phosphorylated tau, and total tau, regardless of the cohort. Correlation between biomarker concentration and cognitive scores was comparable across cohorts, and strongest for NfL, chitinase-3-like protein-1 (YKL40), and glial fibrillary acidic protein. Discussion: The precision of the NTK enables merging of biomarker datasets, after correction for preanalytical confounders. Assessment of multiple cohorts is crucial to increase power in future studies into AD pathogenesis., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). For the Wisconsin studies, CSF assay kits were provided by Roche Diagnostics GmbH. Data were collected under the following grants from the NIH National Institute of Aging: R01 AG027161, R01 AG037639, R01AG054059 UF1AG051216, P50 AG033514, and P30 AG062715. Support was also provided by the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 (Clinical and Translational Sciences). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie (grant agreement No. 847648; LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institute of Health (NIH), USA (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Spatial-temporal patterns of β-amyloid accumulation: a subtype and stage inference model analysis

  • Collij, Lyduine E.
  • Salvadó, Gemma
  • Wottschel, Viktor
  • Mastenbroek, Sophie E.
  • Schoenmakers, Pierre
  • Heeman, Fiona
  • Aksman, Leon
  • Wink, Alle Meije
  • Berckel, Bart N.M.
  • van de Flier, Wiesje M.
  • Scheltens, Philip
  • Visser, Pieter Jelle
  • Barkhof, Frederik
  • Haller, Sven
  • Gispert, Juan Domingo
  • Lopes Alves, Isadora
  • Alzheimer’s Disease Neuroimaging Initiative
  • ALFA Study
Background and objectives: β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data. Methods: amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression. Results: participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were APOE ε4 carriers, and 51.8% were female. A 1-subtype model recovered the traditional amyloid accumulation trajectory, but SuStaIn identified 3 optimal subtypes, referred to as frontal, parietal, and occipital based on the first regions to show abnormality. Of the 788 (26.2%) with strong subtype assignment (>50% probability), the majority was assigned to frontal (n = 415 [52.5%]), followed by parietal (n = 199 [25.3%]) and occipital subtypes (n = 175 [22.2%]). Significant differences across subtypes included distinct proportions of APOE ε4 carriers (frontal 61.8%, parietal 57.1%, occipital 49.4%), participants with dementia (frontal 19.7%, parietal 19.1%, occipital 31.0%), and lower age for the parietal subtype (frontal/occipital 72.1 years, parietal 69.3 years). Higher amyloid (Centiloid) and CSF p-tau burden was observed for the frontal subtype; parietal and occipital subtypes did not differ. At follow-up, most participants (81.1%) maintained baseline subtype assignment and 25.6% progressed to a later stage. Discussion: whereas a 1-trajectory model recovers the established pattern of amyloid accumulation, SuStaIn determined that 3 subtypes were optimal, showing distinct associations with Alzheimer disease risk factors. Further analyses to determine clinical utility are warranted., The project leading to this article has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither the Innovative Medicines Initiative nor the European Union or EFPIA are liable for any use of the information contained herein. The ALFA study received funding from “la Caixa” Foundation (ID 100010434) under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and the Agencia Estatal de Investigación Proyectos de I+D+i Retos Investigación (RTI2018-102261-B-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).